-unusually high volume of trading on the TSX today-
BELLEVILLE, ON, April 19, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today noted substantial trading volume of its shares on the Toronto Stock Exchange.
It has come to the Company's attention that one of its institutional shareholders - the Fonds de solidarité FTQ - has sold their entire holding.
"This has come as a surprise to us as there has been no material change in our business," stated Mr. Graeme McRae, President & CEO of Bioniche Life Sciences Inc. "However, we appreciate the number of investors who have purchased shares today, and we look forward to working with all shareholders to demonstrate the Company's potential."
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets worldwide. The fully-integrated company employs more than 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and One Health. The Company's primary goal is to develop and commercialize products that advance human or animal health and increase shareholder value. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
SOURCE Bioniche Life Sciences Inc.